NasdaqGM:FLGT

Stock Analysis Report

Executive Summary

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Fulgent Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FLGT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.8%

FLGT

11.6%

US Healthcare

9.4%

US Market


1 Year Return

54.5%

FLGT

7.2%

US Healthcare

-6.8%

US Market

Return vs Industry: FLGT exceeded the US Healthcare industry which returned -1.9% over the past year.

Return vs Market: FLGT exceeded the US Market which returned -10% over the past year.


Shareholder returns

FLGTIndustryMarket
7 Day2.8%11.6%9.4%
30 Day-32.4%-4.2%-3.9%
90 Day-25.7%-11.5%-16.5%
1 Year54.5%54.5%8.6%7.2%-4.8%-6.8%
3 Year-5.0%-5.0%29.7%23.9%23.4%15.2%
5 Yearn/a34.8%25.6%41.3%25.7%

Price Volatility Vs. Market

How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?

2.68x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: FLGT ($9.44) is trading above our estimate of fair value ($3.12)

Significantly Below Fair Value: FLGT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: FLGT is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: FLGT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FLGT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FLGT is overvalued based on its PB Ratio (2.4x) compared to the US Healthcare industry average (2.4x).


Next Steps

Future Growth

How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

147.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLGT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: FLGT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FLGT's is expected to become profitable in the next 3 years.

Revenue vs Market: FLGT's revenue (22.2% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: FLGT's revenue (22.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Fulgent Genetics performed over the past 5 years?

22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLGT is currently unprofitable.

Growing Profit Margin: FLGT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FLGT is unprofitable, but has reduced losses over the past 5 years at a rate of 22% per year.

Accelerating Growth: Unable to compare FLGT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FLGT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (14%).


Return on Equity

High ROE: FLGT has a negative Return on Equity (-0.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fulgent Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: FLGT's short term assets ($37.1M) exceed its short term liabilities ($3.7M).

Long Term Liabilities: FLGT's short term assets ($37.1M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: FLGT is debt free.

Reducing Debt: FLGT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable FLGT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: FLGT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24% per year.


Next Steps

Dividend

What is Fulgent Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Ming Hsieh (63yo)

3.92s

Tenure

US$240,000

Compensation

Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics, ...


CEO Compensation Analysis

Compensation vs Market: Ming's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD1.51M).

Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman3.92yrsUS$240.00k36.62% $81.4m
Paul Kim
Chief Financial Officer4.25yrsUS$241.12k1.61% $3.6m
Han Gao
Chief Scientific Officer & Laboratory Director3.58yrsUS$216.30k5.88% $13.1m
Brandon Perthuis
Chief Commercial Officer0.083yrno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Management: FLGT's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman3.92yrsUS$240.00k36.62% $81.4m
John Bolger
Independent Director3.58yrsUS$72.60k0.018% $40.2k
Yun Yen
Independent Director3.58yrsUS$53.50k2.44% $5.4m
James Mulay
Independent Director3.58yrsUS$70.10k0.027% $60.6k
Linda Marsh
Director0.67yrno datano data

3.6yrs

Average Tenure

65yo

Average Age

Experienced Board: FLGT's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fulgent Genetics, Inc.
  • Ticker: FLGT
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$222.335m
  • Shares outstanding: 21.56m
  • Website: https://www.fulgentgenetics.com

Number of Employees


Location

  • Fulgent Genetics, Inc.
  • 4978 Santa Anita Avenue
  • Suite 205
  • Temple City
  • California
  • 91780
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLGTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2016
7F0DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2016

Biography

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 04:45
End of Day Share Price2020/04/08 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.